Telomir Pharmaceuticals Shows Promise for Osteosarcoma Treatment in Humans and Dogs

MIAMI, Sept. 14, 2026 /CourierPR/ -- Telomir Pharmaceuticals, Inc. has announced new research findings from The Ohio State University College of Veterinary Medicine that demonstrate the anti-cancer activity of Telomir-Zn in both human and canine osteosarcoma models. The research, led by Shay Bracha, DVM, MS, DACVIM (Oncology) at Ohio State’s College of Veterinary Medicine, evaluated the compound’s dose-dependent inhibition of cell growth across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine).

According to Bracha, an associate professor at The Ohio State University College of Veterinary Medicine, "Osteosarcoma in large-breed dogs remains devastating, with limited treatment options and poor outcomes. These findings suggest Telomir-Zn may offer a meaningful therapeutic opportunity for veterinary patients. The consistency of anti-tumor activity across both canine and human cell lines is particularly compelling because it positions us to explore efficacy in naturally occurring canine osteosarcoma, a model that could accelerate development for both animals and humans."

The research findings validate the therapeutic potential of Telomir-Zn in osteosarcoma and support further translational investigation. The biological similarities between canine and human osteosarcoma, including genetics, tumor biology, and therapeutic response patterns, make the canine model one of the most clinically predictive disease models available for translational research.

Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, commented, "This research opens a strategic opportunity to develop Telomir-Zn across multiple oncology indications. Our TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment, and we are assessing next steps for potential osteosarcoma development. If successful with either indication, this multi-pronged approach could establish Telomir-Zn as a platform therapy targeting aggressive malignancies, meaningfully expanding our therapeutic scope."

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer. The company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.

The findings from the research could have significant implications for both veterinary and human medicine. The company is now considering the potential for developing Telomir-Zn as a therapy for canine osteosarcoma, which could accelerate clinical development in both species. While the company's immediate focus remains advancing its TNBC program toward site initiation and Phase 1/2 patient enrollment, these preclinical findings position potential osteosarcoma development in canine models as a strategic opportunity.

The mechanism of Telomir-Zn involves targeting intracellular iron and copper homeostasis to modulate epigenetic pathways. The company's strategic focus is on triple-negative breast cancer, where the TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment. The osteosarcoma preclinical findings provide an additional translational opportunity to validate the mechanism in a naturally occurring disease model (canine) while simultaneously advancing the lead TNBC indication.

These findings underscore the potential of Telomir-Zn to address unmet clinical needs in both human and veterinary oncology. The company's dual-pathway approach could expand the therapeutic indication profile while advancing its platform. The research opens a new avenue for developing a platform therapy targeting aggressive malignancies, potentially offering meaningful therapeutic opportunities for both animals and humans.